HOLLENCREST CAPITAL MANAGEMENT - INTERCEPT PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
HOLLENCREST CAPITAL MANAGEMENT ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$278,100
+67.6%
15,0000.0%0.03%
+82.4%
Q2 2023$165,900
-17.6%
15,0000.0%0.02%
-22.7%
Q1 2023$201,450
+8.6%
15,0000.0%0.02%
-4.3%
Q4 2022$185,550
-11.2%
15,0000.0%0.02%
-11.5%
Q3 2022$209,000
+1.0%
15,0000.0%0.03%
+8.3%
Q2 2022$207,000
-15.2%
15,0000.0%0.02%
+9.1%
Q1 2022$244,0000.0%15,0000.0%0.02%
+15.8%
Q4 2021$244,00015,0000.02%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2023
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 234,375$23,623,00022.67%
Boxer Capital, LLC 600,000$60,474,0007.47%
DLD Asset Management, LP 834,600$84,136,0005.77%
GREAT POINT PARTNERS LLC 200,000$20,158,0002.55%
BB BIOTECH AG 575,719$58,027,0001.86%
Elk Creek Partners, LLC 207,657$20,930,0001.74%
ALTRINSIC GLOBAL ADVISORS LLC 277,944$28,014,0001.34%
Sarissa Capital Management LP 54,000$5,442,0001.21%
QCM Cayman, Ltd. 2,181$220,0000.90%
Opus Point Partners Management, LLC 3,534$356,0000.78%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders